If a child’s HSV lesions continue to spread despite appropriate acyclovir, switching to valacyclovir can sound like escalation. But if the virus cannot activate acyclovir, changing how the drug is delivered may not solve the problem. The mechanism helps answer a more useful question than simply naming the target: which step has failed, and what does that mean for the next decision?
This reasoning is especially relevant when HSV is progressing during treatment in an immunocompromised child. A recurrence after treatment ends is different: acyclovir suppresses active viral replication but does not clear latent HSV from sensory ganglia, so recurrence alone does not establish resistance.
Separate the activation step from the drug target
Acyclovir is a guanosine analogue. In an HSV-infected cell, viral thymidine kinase (TK) adds the first phosphate. Host-cell enzymes add two more, producing acyclovir triphosphate—the active form of the drug.
Acyclovir triphosphate competes with the natural nucleotide dGTP and inhibits viral DNA polymerase. If incorporated into viral DNA, it prevents further chain extension because it lacks the 3′ hydroxyl needed to add the next nucleotide. The board-ready sequence is viral TK activates acyclovir; acyclovir triphosphate inhibits viral DNA polymerase and terminates DNA-chain growth.
| Step | What happens | Why it matters |
|---|---|---|
| Viral activation | HSV TK begins phosphorylation of acyclovir | Preferential activation contributes to selectivity; TK is not the main drug target. |
| Host-cell activation | Cellular enzymes produce acyclovir triphosphate | The triphosphate is the active antiviral form. |
| Viral DNA synthesis | The active drug inhibits viral DNA polymerase and interrupts chain extension | DNA replication slows or stops in actively infected cells. |
A common exam trap is to say that acyclovir works by inhibiting thymidine kinase. TK is the activation gate; viral DNA polymerase is the target. Activation is preferential in infected cells, not an absolute guarantee that only infected cells encounter or process the drug.
Resistance can break either link
Resistance follows the same pathway. A virus with absent, reduced, or altered TK activity may fail to activate enough acyclovir. HSV TK is dispensable for viral replication in cell culture and certain tissues, so a TK-deficient virus can remain viable. Less commonly, changes in viral DNA polymerase can reduce susceptibility to the active drug.
| Resistance site | What changes | Mechanistic consequence |
|---|---|---|
| Viral thymidine kinase | TK is absent, reduced, or less able to phosphorylate acyclovir | Too little active acyclovir triphosphate is produced. |
| Viral DNA polymerase | The drug target changes | The active drug may bind or inhibit the enzyme less effectively. |
These are mechanisms, not bedside diagnostic criteria. Slow healing can have other explanations, including inadequate drug exposure, an incorrect or incomplete diagnosis, secondary infection, or severe impairment of immune control. Resistance becomes more concerning when lesions continue to progress during an adequate course—particularly in an immunocompromised child—rather than when a new episode appears after therapy has ended.
Why valacyclovir may not be the answer
Valacyclovir is converted in the body to acyclovir. It can improve oral delivery of acyclovir, which may help when the problem is inadequate exposure by the oral route. But it does not bypass the viral TK activation step. If HSV resistance is caused by a TK defect, valacyclovir delivers the same antiviral active molecule into the same pathway; it is not a new mechanism.
Famciclovir is converted to penciclovir, which also depends on viral TK activation. Cross-resistance is common, so it should not be assumed to solve a TK-related resistance problem either.
Foscarnet offers a mechanistic contrast. It inhibits viral DNA polymerase directly at a different binding site and does not require phosphorylation by TK. That is why it can retain activity against many TK-deficient HSV strains. Some viral DNA-polymerase mutations can also reduce foscarnet susceptibility. Foscarnet carries important renal and electrolyte risks; its use requires specialist oversight and monitoring.
Turn apparent treatment failure into a focused reassessment
Before labeling a child’s HSV acyclovir-resistant, confirm the clinical picture and check whether the prescribed regimen is reaching the child as intended: dose and route, doses actually administered, ability to take or absorb oral medication, and renal function where it affects dosing. Reconsider whether the lesions are HSV and whether another process is complicating healing. In a child with suspected neonatal, CNS, or disseminated HSV, this mechanism discussion is not a reason to delay urgent antiviral treatment.
If lesions are progressing despite appropriate therapy, especially in an immunocompromised child, seek pediatric infectious-disease input and consider resistance testing. A lesion culture can provide virus for phenotypic susceptibility testing. A positive HSV PCR from a lesion detects HSV DNA; by itself, it does not show whether the virus is acyclovir-resistant. Phenotypic testing of a cultured isolate or targeted sequencing of resistance-associated genes may be considered where available; access, scope, and turnaround vary.
When resistance is strongly suspected or confirmed, a specialist may change therapy before results are available if the child’s condition warrants it. Pediatric HIV opportunistic-infection guidance identifies foscarnet as the treatment of choice for acyclovir-resistant HSV in that population; decisions for other children should be individualized with pediatric infectious-disease expertise.
Practical takeaways
- Acyclovir’s first phosphorylation step depends on viral TK; the active triphosphate inhibits viral DNA polymerase.
- TK activates acyclovir—it is not the main drug target. Resistance can arise at the TK activation step or at DNA polymerase.
- Valacyclovir improves acyclovir delivery but does not bypass TK-dependent activation; relapse after treatment ends alone does not prove resistance.
- Progression during appropriate therapy warrants reassessment and, when feasible, susceptibility testing. Foscarnet bypasses TK but needs specialist management because of toxicity.
